A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.
Alireza FaridarAbdulmunaim M EidAaron D ThomeWeihua ZhaoDavid R BeersMaria B PascualMohammad O NakawahGustavo C RomanCharles S DavisMichael GrundmanJoseph C MasdeuStanley H AppelPublished in: Translational neurodegeneration (2023)
gov/ct2/show/NCT05821153.
Keyphrases
- low dose
- open label
- clinical trial
- image quality
- computed tomography
- high dose
- cognitive decline
- dual energy
- phase ii
- contrast enhanced
- phase iii
- phase ii study
- study protocol
- magnetic resonance imaging
- positron emission tomography
- squamous cell carcinoma
- randomized controlled trial
- magnetic resonance
- radiation therapy
- mild cognitive impairment